Bisphosphonates and Miscellaneous Bone Drugs

1. Introduction / Overview

Bone remodeling is a continuous physiological process regulated by a coordinated balance between osteoclast‑mediated resorption and osteoblast‑mediated formation. Disruption of this equilibrium underlies a spectrum of metabolic bone disorders, including osteoporosis, osteolytic bone metastases, Paget’s disease, and malignant hypercalcemia. Pharmacologic agents that intervene in bone turnover have become integral to the management of these conditions. Among them, bisphosphonates represent the most widely utilized class, while a variety of ancillary agents—such as denosumab, teriparatide, abaloparatide, romosozumab, and selective estrogen receptor modulators—expand the therapeutic armamentarium. This chapter provides a comprehensive review of bisphosphonates and other bone‑active drugs, emphasizing their pharmacology, clinical applications, and safety profiles. Students will acquire a deeper understanding of the mechanistic rationale for drug selection and dosing strategies, as well as the nuances of patient‑specific considerations.

Learning Objectives

• Identify the structural features that distinguish bisphosphonates from other bone‑targeting agents.
• Explain the molecular mechanisms by which bisphosphonates and related drugs modulate osteoclast activity.
• Compare the pharmacokinetic properties and dosing regimens of major bisphosphonate preparations.
• Recognize the approved indications, off‑label uses, and contraindications for bisphosphonates and miscellaneous bone drugs.
• Summarize the common and serious adverse effects, and outline strategies to mitigate toxicity.

2. Classification

2.1 Bisphosphonate Chemical Classes

Bisphosphonates possess a phosphonate backbone (P–C–P) and are classified according to the substituent at the carbon atom (R1) and the side chain (R2). The R1 group modulates affinity for hydroxyapatite, while the R2 side chain determines potency and mechanism of action. Early bisphosphonates (e.g., etidronate) contain a non‑nitrogenous R2, whereas second‑generation agents (e.g., clodronate, alendronate) feature a nitrogen atom within the R2 side chain. Third‑generation bisphosphonates (e.g., zoledronic acid, ibandronic acid) possess additional nitrogen atoms or heterocyclic rings, conferring markedly higher potency and distinct metabolic pathways.

2.2 Other Bone‑Targeting Agents

Beyond bisphosphonates, several pharmacologic classes act on bone metabolism via distinct mechanisms:

• Denosumab – a monoclonal antibody that neutralizes RANKL, inhibiting osteoclast differentiation.
• PTH analogues – teriparatide and abaloparatide stimulate osteoblastic activity via the PTH1 receptor.
• Romosozumab – a sclerostin‑blocking monoclonal antibody that enhances bone formation and reduces resorption.
• Selective Estrogen Receptor Modulators (SERMs) – raloxifene and bazedoxifene modulate estrogen receptors to reduce bone resorption.
• Calcitonin – a hormone that directly inhibits osteoclast function.

3. Mechanism of Action

3.1 Bisphosphonate Pharmacodynamics

Bisphosphonates exhibit a high affinity for hydroxyapatite crystals within the bone matrix. Upon remodeling, osteoclasts internalize bisphosphonate‑laden vesicles. Nitrogenous bisphosphonates undergo a metabolic transformation in osteoclasts, generating non‑hydrolyzable analogues of ATP intermediates (e.g., ATPγS). These analogues inhibit farnesyl diphosphate synthase (FPPS) within the mevalonate pathway, preventing the prenylation of small GTPases such as RhoA, Ras, and Rac1. Consequently, osteoclast cytoskeletal organization, vesicular trafficking, and resorptive capacity are disrupted, leading to osteoclast apoptosis. This cascade reduces bone resorption and shifts the remodeling balance toward bone formation.

Non‑nitrogenous bisphosphonates are incorporated into non‑hydrolyzable ATP analogues, causing osteoclast apoptosis through direct cytotoxicity.

3.2 Mechanisms of Miscellaneous Bone Drugs

• Denosumab binds RANKL with high affinity, preventing engagement with its receptor RANK on osteoclast precursors. This blockade reduces osteoclastogenesis, activation, and survival.
• PTH Analogues stimulate osteoblast proliferation and differentiation via cyclic AMP production, upregulating bone‑matrix proteins and promoting mineralization.
• Romosozumab neutralizes sclerostin, a glycoprotein secreted by osteocytes that antagonizes Wnt/β‑catenin signaling. Inhibition of sclerostin restores Wnt activity, enhancing osteoblast function and simultaneously decreasing RANKL expression.
• Calcitonin binds to calcitonin receptors on osteoclasts, inhibiting proton pump activity and reducing resorptive capacity.

4. Pharmacokinetics

4.1 Bisphosphonate Absorption

Oral bisphosphonates exhibit poor gastrointestinal absorption, typically <1 % of the administered dose, and are influenced by food intake, gastric pH, and concurrent medications. Intravenous bisphosphonates achieve 100 % bioavailability and bypass first‑pass metabolism. The absorption of alendronate and risedronate is markedly diminished when taken with dairy products or antacids containing calcium or magnesium. Consequently, patients are advised to ingest bisphosphonates on an empty stomach and remain upright for at least 30 minutes.

4.2 Distribution and Bone Binding

After systemic absorption, bisphosphonates rapidly distribute to bone due to their high affinity for hydroxyapatite. The fraction bound to bone can represent up to 90 % of the circulating drug, creating a large depot that slowly releases the drug over months to years. The extent of bone binding correlates with bisphosphonate potency and chemical structure; third‑generation agents such as zoledronic acid display higher bone affinity than first‑generation compounds.

4.3 Metabolism and Excretion

Bisphosphonates are not metabolized by hepatic enzymes and are excreted unchanged via the kidneys. Renal clearance is the principal route, with a glomerular filtration rate (GFR) threshold of approximately 30 mL min⁻¹ required to prevent accumulation. In patients with reduced renal function, dosage adjustments or alternative agents are necessary. The terminal half‑life of bisphosphonates in bone ranges from weeks to several years, reflecting the slow release from the matrix.

4.4 Pharmacokinetics of Miscellaneous Bone Drugs

• Denosumab is administered subcutaneously every six months; it undergoes catabolism via the reticuloendothelial system, with negligible renal excretion. Its half‑life is approximately 25 days.
• PTH Analogues (teriparatide, abaloparatide) are administered subcutaneously daily; they are metabolized by peptidases and eliminated primarily via the kidneys. The half‑life is 1–3 hours.
• Romosozumab is given subcutaneously once monthly; it is cleared through proteolytic degradation and has a half‑life of 32 days.
• Calcitonin (nasal spray) is absorbed through the nasal mucosa; it is rapidly degraded by peptidases and has a half‑life of 20–30 minutes.

5. Therapeutic Uses / Clinical Applications

5.1 Bisphosphonates

• Primary osteoporosis in postmenopausal women and men over 50 years.
• Secondary osteoporosis secondary to glucocorticoid therapy, androgen deprivation therapy, or chronic kidney disease.
• Osteolytic bone metastases from breast, prostate, or lung carcinoma.
• Paget’s disease of bone, with high doses of alendronate or zoledronic acid.
• Prevention of skeletal‑related events in multiple myeloma.

5.2 Miscellaneous Bone Drugs

• Denosumab: Postmenopausal and glucocorticoid‑induced osteoporosis; prevention of vertebral fractures in patients intolerant to bisphosphonates.
• Teriparatide: Severe osteoporosis with high fracture risk; secondary hyperparathyroidism; hypocalcemia following parathyroidectomy.
• Abaloparatide: Postmenopausal osteoporosis with high fracture risk.
• Romosozumab: Postmenopausal osteoporosis with very high fracture risk; patients with inadequate response to bisphosphonates.
• Calcitonin: Acute back pain due to vertebral compression fractures; mild osteoporosis in patients with contraindications to other agents.
• SERMs: Postmenopausal osteoporosis in patients at increased risk of venous thromboembolism.

5.3 Off‑Label and Emerging Uses

Bisphosphonates have been explored for fracture prevention in men with prostate cancer, for treatment of bone pain in metastatic disease, and for enhancing fracture healing in osteoporotic fractures. Emerging evidence suggests potential roles in preventing bone loss associated with spaceflight and in the management of bone loss in HIV‑infected patients on antiretroviral therapy. However, these indications remain investigational.

6. Adverse Effects

6.1 Common Side Effects

• Gastrointestinal irritation, esophagitis, or ulceration with oral bisphosphonates.
• Acute phase reactions (fever, myalgia) following intravenous bisphosphonate infusion.
• Hypocalcemia, particularly in patients with vitamin D deficiency or severe renal impairment.
• Jaw osteonecrosis in patients receiving high‑dose intravenous bisphosphonates or with invasive dental procedures.
• Renal dysfunction due to tubular injury from bisphosphonate accumulation.

6.2 Serious or Rare Reactions

Bisphosphonate‑associated osteonecrosis of the jaw (BRONJ) has an incidence of ~1–2 % in oncology patients receiving high‑dose therapy, and a lower incidence (0.01–0.1 %) in osteoporosis cohorts. Atypical femoral fractures, defined by transverse fractures with minimal trauma, have been reported most frequently with long‑term bisphosphonate therapy. Recent registr

References

1. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
2. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
3. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
4. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
5. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
6. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
7. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
8. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.